PRESS RELEASE: Future of Wound Care: Medical Cold Plasma Brings New Hope for Patients with Chronic Wounds

• Innovative cold plasma therapy for the treatment of chronic wounds is soon to become part of standard care
• The companies neoplas med, terraplasma medical and Cinogy System form a consortium to test the method
• Cold plasma therapy offers the promising possibility of accelerating wound healing and improving the quality of life of these patients.

Berlin 25.09.2023 In medicine, cold plasma is used, among other things, to treat chronic and poorly healing wounds. To ensure that the “young” cold plasma therapy will soon be reimbursed by health insurers, neoplas med submitted an application for testing as early as April 2021, which was approved by the Federal Joint Committee (G-BA) in February 2023.

Now the three leading companies neoplas med GmbH, terraplasma-medical GmbH and Cinogy System GmbH have announced that they are forming a consortium to commission the trial study in the method evaluation procedure of the Federal Joint Committee (G-BA).

In Germany, approximately 900,000 people suffer from chronic and poorly healing wounds. Diabetics or people with wound healing disorders are particularly affected. Cold plasma therapy has the potential to sustainably improve wound healing and the quality of life of these patients. The method is already used in many practices and clinics, but is not yet a standard treatment by health insurance companies.

The forerunners of cold plasma medicine in Germany and developers of the most important physical processes- neoplas med for the jet cold plasma process and terraplasma medical and Cinogy for the DBE cold plasma process- for the generation of cold plasma have joined forces to promote the introduction of cold plasma therapy into standard medical care.

The aim of the trial study, under the scientific direction of Prof. Dr. Dr. Hans-Robert Metelmann (Chairman of the Board of the National Center for Plasma Medicine) as Chief Medical Investigator, is to provide the scientific and statistical basis for a benefit assessment by the G-BA with its Chairman Professor Hecken. Due to the different wound types to be considered in the study, a high number of participants and a trial duration of several years can be assumed.

The consortium is determined to make this successful therapy, which has already been available for several years, accessible to the majority of patients with statutory health insurance in standard care. Cold plasma therapy could thus represent a significant innovation in healthcare and offer many people with chronic wounds new hope for a better quality of life.